Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414257 | 0.82 | GAA (0.39) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6419677 | 0.77 | GAA (0.49) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6419799 | 0.75 | SMN1; SMN2 (0.48) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6416039 | 0.74 | MEN1 (0.44) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6414619 | 0.74 | MEN1 (0.46) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6416982 | 0.73 | MAPT (0.45) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6416313 | 0.72 | MAPT (0.47) | GAAKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6414113 | 0.71 | EGFR (0.49) | KMT2AMEN1POLBHTT | |
| SCHEMBL3061131 | 0.68 | POLB (0.45) | KMT2AMEN1POLBLMNAHTT | |
| SCHEMBL6435103 | 0.68 | HTT (0.33) | KMT2APOLBLMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | GAA 3186/4885KMT2A 3640/4885MEN1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.